Retinal vascular events after intravitreal bevacizumab

Acta Ophthalmologica

Volumn 88, Issue 7, 2010, Pages 730-735

  Mansour, Ahmad M ^a   Bynoe, Leon A ^b   Welch, John C ^c   Pesavento, Richard ^d   Mahendradas, Padmamalini ^e   Ziemssen, Focke ^f   Pai, Sivakami A ^e  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Retina Associates of Coral Springs   (United States)

^c Retina Clinic   (United States)

^d Retina Consultants of Southern California   (United States)

^e Narayana Nethralaya ^*  (India)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

bevacizumab; branch retinal artery occlusion; branch retinal vein occlusion; capillary occlusion; central retinal artery occlusion; central retinal vein occlusion

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BRANCH RETINAL ARTERY OCCLUSION; BRANCH RETINAL VEIN OCCLUSION; CAROTID ARTERY DISEASE; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GLAUCOMA; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MIGRAINE; PRIORITY JOURNAL; SMOKING HABIT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; EYE DISEASES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GLAUCOMA; HUMANS; HYPERTENSION; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETINAL ARTERY OCCLUSION; RETINAL DISEASES; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; VASOCONSTRICTOR AGENTS; VITREOUS BODY;

EID: 78349233145     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01535.x     Document Type: Article

References (25)

1. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, &, Humayun MS, (2007): The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 48: 5708 - 5715.
2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. (2007): Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (avastin) for diabetic macular edema. Results from the Pan-American Collaborative Study Group at 6-month follow-up. Ophthalmology 114: 743 - 750.
3. Avunduk AM, Dinç H, Kapiciolu Z, Uurlu S, Dayanir V, &, Korkmaz E, (1999): Arterial blood flow characteristics in central retinal vein occlusion and effects of panretinal photocoagulation treatment: an investigation by colour Doppler imaging. Brit J Ophthalmol 83: 50 - 53.
4. Cannistra SA, Matulonis UA, Penson RT, et al. (2007): Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180 - 5186.
5. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, &, Scott IU, (2007): Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27: 141 - 149.
6. Dafer RM, Schneck M, Friberg TR, &, Jay WM, (2007): Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 22: 201 - 204.
7. Eremina V, Ashley Jefferson J, Kowalewska J, et al. (2008): VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129 - 1136.
8. Falkenstein IA, Cheng L, &, Freeman WR, (2007): Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 27: 1044 - 1047.
9. Fung AE, Rosenfeld PJ, &, Reichel E, (2006): The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Brit J Ophthalmol 90: 1344 - 1349.
10. Hayreh SS, Van Heuven WA, &, Hayreh MS, (1978): Experimental retinal vascular occlusion. I. Pathogenesis of central retinal vein occlusion. Arch Ophthalmol 96: 311 - 323.
11. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, &, Gale J, (2007): Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42: 807 - 811.
12. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, &, Temel SG, (2007): Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773 - 1781.
13. Kim KS, Chang HR, &, Song S, (2008): Ischaemic change after intravitreal bevacizumab (avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 86: 925 - 927.
14. Liu MH, Jin H, Floten HS, Ren Z, Yim AP, &, He GW, (2002): Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery. Ann Thorac Surg 73: 819 - 824.
15. Miller K, Wang M, Gralow J, et al. (2007): Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Eng J Med 357: 2666 - 2676.
16. Neubauer AS, Kook D, Haritoglou D, Priglinger SG, Kampik A, Ulbig MW, &, Ceklic L, (2007): Bevacizumab and retinal ischemia. Ophthalmology 114: 2096.
17. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Tubingen Bevacizumab Study Group &, Schraermeyer U, (2007): Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995 - 1002.
18. Roncalli J, Delord JP, Galinier M, Massabuau P, Lescure M, Fauvel JM, &, Azria D, (2006): Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event. Ann Oncol 17: 1177 - 1178.
19. Ross R, (1999): Atherosclerosis - an inflammatory disease. New Eng J Med 340: 115 - 126.
20. Scappaticci FA, Skillings JR, Holden SN, et al. (2007): Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232 - 1239.
21. Shima C, Sakaguchi H, Gomi F, et al. (2008): Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86: 372 - 376.
22. Soliman W, Vinten M, Sander B, Soliman KA, Yehya S, Rahman MS, &, Larsen M, (2008): Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 86: 365 - 371.
23. Steeghs N, Gelderblom H, Roodt J, et al. (2008): Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14: 3470 - 3476.
24. Vinten M, Larsen M, Lund-Andersen H, Sander B, &, La Cour M, (2007): Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. Acta Ophthalmol Scand 85: 21 - 26.
25. Yokoyama K, Chochi T, Kimoto K, Shinoda K, &, Nakatsuka K, (2008): Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol 86: 927 - 928.